PPBT

Purple Biotech Ltd

Add to Watchlist

Advanced Chart

2.150

0(0.000%)1D

Overview
Forecast
Valuation
Earnings

Line

Candle

YTD

High

2.1564

Open

2.130

VWAP

2.15

Vol

10.36K

Mkt Cap

1.30B

Low

2.1101

Amount

22.29K

EV/EBITDA(TTM)

Total Shares

26.11M

-46.57K

EV/OCF(TTM)

P/S(TTM)

Purple Biotech Ltd, formerly Kitov Pharma Ltd, is an Israel-based clinical-stage company that develops drugs that overcome tumor-immune evasion and drug resistancetreat pain. Main products of the Company is NT-219 i CM-24. CM-24 is a monoclonal antibody blockin and NT-219 is a small molecule bi-specific inhibitor of two key cancer resistance pathways. The Company is also the owner of Consensi, a fixed-dose combination of celecoxib and amlodipine besylate, for the simultaneous treatment of osteoarthritis pain and hypertension.

Market Estimates

Earnings Estimates

Revenue

YoY Chg

EPS

YoYChg

FY2025Q3

FY2025Q2

FY2025Q1

-0.260

-80.98%

-0.210

-86.78%

0.000

-100%

Estimates Revision

The market is revising No Change the revenue expectations for Purple Biotech Ltd (PPBT) for FY2025, with the revenue forecasts being adjusted by % over the past three months. During the same period, the stock price has changed by -4.02%.

EPS Estimates for FY2025

No Change

0.00%

In Past 3 Month

Stock Price

Go Down

-4.02%

In Past 3 Month

1 Analyst Rating

1481.40% Upside

Wall Street analysts forecast PPBT stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for PPBT is 34.00 USD with a low forecast of 34.00 USD and a high forecast of 34.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

1 Buy

0 Hold

0 Sell

Moderate Buy

1481.40% Upside

Current: 2.150

Low

34.00

Averages

34.00

High

34.00

1481.40% Upside

Current: 2.150

Low

34.00

Averages

34.00

High

34.00

HC Wainwright & Co.

Emily Bodnar

Strong Buy

Reiterates

$33

2024-11-15

Reason

HC Wainwright & Co.

Emily Bodnar

Price Target

$33

2024-11-15

Reiterates

Strong Buy

Reason

HC Wainwright & Co.

Emily Bodnar

Strong Buy

Maintains

$8 → $33

2024-09-20

Reason

HC Wainwright & Co.

Emily Bodnar

Price Target

$8 → $33

2024-09-20

Maintains

Strong Buy

Reason

HC Wainwright & Co.

Emily Bodnar

Strong Buy

Maintains

$10 → $8

2024-08-19

Reason

HC Wainwright & Co.

Emily Bodnar

Price Target

$10 → $8

2024-08-19

Maintains

Strong Buy

Reason

See All Ratings

Valuation Metrics

The current forward P/E ratio for Purple Biotech Ltd (PPBT.O) is -2.20, compared to its 5-year average forward P/E of -6.47. For a more detailed relative valuation and DCF analysis to assess Purple Biotech Ltd 's fair value, click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

N/A

5Y Average PE

-6.47

Current PE

-2.20

Overvalued PE

15.15

Undervalued PE

-28.08

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

N/A

5Y Average EV/EBITDA

0.00

Current EV/EBITDA

0.00

Overvalued EV/EBITDA

0.00

Undervalued EV/EBITDA

0.00

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

N/A

5Y Average PS

2.27

Current PS

0.00

Overvalued PS

5.93

Undervalued PS

-1.40